European Penny Stocks To Watch In May 2025

The European market has shown resilience, with the pan-European STOXX Europe 600 Index rising by 2.10% as optimism improved following a de-escalation in U.S.-China trade tensions. In such an environment, penny stocks—typically smaller or relatively new companies—can offer unique opportunities for investors seeking growth potential at an affordable price point. While the term 'penny stocks' may seem outdated, their relevance persists as they often combine value and growth potential when backed by strong financials.

Top 10 Penny Stocks In Europe

Click here to see the full list of 439 stocks from our European Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Greenland Resources (DB:M0LY)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Greenland Resources Inc. is a mining company focused on the acquisition, exploration, and development of mineral projects in Greenland, with a market cap of €62.21 million.

Operations: Revenue Segments: Currently, there are no reported revenue segments for this mining-focused entity.

Market Cap: €62.21M

Greenland Resources Inc., a pre-revenue mining company, recently announced a private placement to raise CAD 3 million, reflecting its ongoing capital needs. The company is progressing with its Malmbjerg Molybdenum Project in Greenland and has signed an off-take agreement with Finnish Outokumpu for molybdenum oxide supply. Despite having no long-term liabilities and being debt-free, Greenland Resources remains unprofitable with volatile share prices. The recent inclusion of magnesium in its exploitation license could enhance project value amid global supply concerns, but the company's short cash runway highlights financial challenges typical of penny stocks in resource exploration stages.

• Click here and access our complete financial health analysis report to understand the dynamics of Greenland Resources.
• Review our historical performance report to gain insights into Greenland Resources' track record.

Lindex Group Oyj (HLSE:LINDEX)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Lindex Group Oyj operates in the retail sector both in Finland and internationally, with a market cap of €472.27 million.

Operations: The company generates revenue from its Lindex segment, which accounts for €624.5 million, and the Stockmann segment, contributing €309.2 million.

Market Cap: €472.27M

Lindex Group Oyj, operating in the retail sector, has experienced a challenging year with net losses increasing to €20.2 million for Q1 2025 from €15.4 million the previous year. Despite a stable management team and a reduction in debt-to-equity ratio over five years, the company's profitability remains under pressure with declining profit margins and negative earnings growth of 50% last year. However, Lindex's operating cash flow effectively covers its debt obligations at 89.6%, providing some financial stability amidst market volatility. The company forecasts modest revenue growth of up to 4% for 2025 but faces potential foreign exchange impacts on earnings.

• Dive into the specifics of Lindex Group Oyj here with our thorough balance sheet health report.
• Explore Lindex Group Oyj's analyst forecasts in our growth report.

H&R GmbH KGaA (XTRA:2HRA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: H&R GmbH & Co. KGaA manufactures and sells chemical-pharmaceutical raw materials and injection molded precision plastic parts globally, with a market cap of €184.99 million.

Operations: H&R GmbH & Co. KGaA has not reported specific revenue segments, but it operates in the global market producing chemical-pharmaceutical raw materials and precision plastic parts.

Market Cap: €184.99M

H&R GmbH & Co. KGaA, with a market cap of €184.99 million, has shown resilience in the penny stock space despite challenges. The company reported Q1 2025 sales of €345.84 million and net income of €1.89 million, indicating modest growth from the previous year. While it maintains a stable dividend payout, its earnings growth has been negative recently, contrasting with past profitability improvements over five years. The company's financial health is supported by short-term assets exceeding liabilities and satisfactory debt levels relative to equity, though its low return on equity and high volatility remain concerns for investors seeking stability in this segment.

• Click here to discover the nuances of H&R GmbH KGaA with our detailed analytical financial health report.
• Understand H&R GmbH KGaA's earnings outlook by examining our growth report.

Next Steps

• Investigate our full lineup of 439 European Penny Stocks right here.
• Interested In Other Possibilities? AI is about to change healthcare. These 21 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com